News stories on health policy developments from the Hill and their effect on the pharmaceutical industry
|
May 1, 2013
By:
Jill Wechsler
Legal battles and regulatory missteps undermine access to low-cost generics, at home and abroad, writes Jill Wechsler.
|
April 1, 2013
By:
Jill Wechsler
There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices.
|
March 1, 2013
By:
Jill Wechsler
Pressure for action on key enforcement and regulatory issues may prompt congressional action this year.
|
|
February 1, 2013
By:
Jill Wechsler
More new medicines gained market approval in 2012, but marketers face resistance from payers looking to cut healthcare spending, writes Jill Wechsler.
|
January 1, 2013
By:
Jill Wechsler
FDA policies will reshape drug development, while pressure to cut healthcare spending may alter drug coverage and pricing.
|
December 1, 2012
By:
Jill Wechsler
Tax and budget decisions will shape the healthcare market and drug research and regulation.
|
|
November 1, 2012
By:
Jill Wechsler
While the nation was embroiled in the presidential elections, a number of important legal and regulatory issues absorbed pharmaceutical executives, writes Jill Wechsler.
|
|
October 1, 2012
By:
Jill Wechsler
New user fee programs precipitate major changes at an agency under constant and intense scrutiny, writes Jill Wechsler.
|
|
September 1, 2012
By:
Jill Wechsler
Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
